A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

“While GLP-1-based therapies have revolutionized patient care for obesity ... harmful triglycerides and cholesterol while ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Weight loss drugs are incredibly sought-after, but they’re also often difficult to obtain due to limited insurance coverage ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases ...

The discovery could lead to a new treatment for millions of people with obesity and type 2 diabetes who do not respond well to current treatments.

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

RJVA-002 is a locally administered AAV9 viral vector that expresses human GIP and GLP-1 hormones from a human insulin promoter. We are confident that our novel pipeline will position us among the ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.